Maravai LifeSciences Holdings, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter financial breakdown.
Business context
Maravai supplies life-sciences products used in biopharmaceutical research, development and manufacturing. Its two continuing segments are Nucleic Acid Production, including mRNA and CleanCap products, and Biologics Safety Testing. The company sold its Protein Detection business in September 2021. Management identifies Adjusted EBITDA and revenue as key performance measures.
Financial performance
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $883.0 million | $799.2 million | +10.5% |
| Gross profit / gross margin | $714.0 million / 80.9% | $658.7 million / 82.4% | Margin down about 1.5 percentage points |
| Operating income / margin | $574.2 million / 65.0% | $554.6 million / 69.4% | Income +3.5% |
| Net income | $490.7 million | $469.3 million | +4.6% |
| Net income attributable to Maravai | $220.2 million | $182.0 million | +21.0% |
| Diluted EPS attributable to Maravai | $1.67 | $1.56 | Increased |
| Adjusted EBITDA (non-GAAP) | $637.8 million | $582.8 million | +9.4% |
| Cash from operations | $536.0 million | $368.6 million | Increased |
| Adjusted Free Cash Flow (non-GAAP) | $590.9 million | $565.8 million | Increased |
Revenue mix shifted further toward Nucleic Acid Production: $813.1 million, up 14.2%, or 92.1% of revenue. Biologics Safety Testing generated $69.9 million, up 2.2%. FY2021 included $19.0 million from the divested Protein Detection segment.
Cost of revenue increased 20.2%, faster than revenue, reflecting an $8.0 million inventory reserve increase, $6.6 million higher quality-control costs, acquisition-related amortization and added personnel and facility costs. Higher costs and expenses reduced gross and operating margins. Adjusted EBITDA increased, but its margin was approximately 72.2%, versus 72.9% in FY2021.
Cash, liquidity and debt
- Cash at year-end was $632.1 million, compared with $551.3 million a year earlier. Net cash provided by operating activities was $536.0 million; investing activities used $267.6 million and financing activities used $187.5 million.
- Investing cash outflows included $239.0 million net cash paid for MyChem and $17.1 million of property and equipment purchases. Reported FY2022 capital expenditures were $46.9 million, net of government funding.
- Year-end debt principal was $538.6 million; the balance-sheet carrying amount, net of issuance costs, was $527.4 million. No revolving-credit borrowings were outstanding. The term loan’s stated interest rate was 6.96%, and it matures in October 2027. The company reported compliance with debt covenants.
- The company held a $500 million interest-rate cap expiring January 2025. Management stated cash, operating cash flow and access to credit facilities were expected to meet requirements over the next 12 months and beyond.
- The $718.2 million Tax Receivable Agreement (TRA) liability is a substantial future cash obligation. The company estimates payments of approximately $42.3 million to $63.3 million annually over the next 14 years, subject to assumptions and actual tax benefits.
Material changes, outlook and risks
- COVID-19 exposure: Management estimates COVID-19-related products and services accounted for 67.9% of FY2022 revenue, down from 69.7% in FY2021. CleanCap revenue was $660.5 million, of which an estimated $599.8 million was attributable to COVID-19-related demand. Management expected substantial future declines from pandemic highs and cited customers’ unused inventory as a potential additional headwind.
- Customer concentration: The largest customers represented 63.7% of total revenue in FY2022, versus 68.1% in FY2021. BioNTech accounted for 34.8% and Pfizer for 26.4% of FY2022 revenue. Reduced demand or loss of a major customer could materially affect results.
- Investment and capacity: FY2023 capital expenditures were projected at $55 million to $65 million, net of anticipated government funding, mainly for the Flanders San Diego facility. BARDA agreed to fund 50% of eligible construction and validation costs, up to $38.8 million, subject to conditions; the agreement includes public-health-emergency access and pricing obligations.
- Acquisitions: Maravai acquired MyChem in January 2022 for total consideration of approximately $257.9 million. It completed the Alphazyme acquisition in January 2023 for $70 million base cash consideration plus potential performance payments of up to $75 million.
- Other risks and unusual items: Risks include uncertain COVID-related demand, customer and supplier concentration, economic and supply-chain pressures, product quality, competition, regulation and intellectual-property protection. The filing describes past quality issues involving some mRNA/CleanCap products and HCP ELISA kits. MyChem-related contingent consideration was remeasured down by $7.8 million in 2022. The 2022 audit opinion was unqualified; the TRA liability was identified as a critical audit matter.
Important facts for investors to verify
- Whether non-COVID demand grows sufficiently to offset the expected decline in COVID-related revenue, including customer inventory levels and order commitments.
- Revenue and exposure by major customer, particularly BioNTech and Pfizer, and whether concentration is changing.
- Actual margins, inventory reserves, quality-control costs and cash generation as new facilities ramp and demand changes.
- Debt terms, variable-rate exposure and the timing and funding of TRA payments; TRA estimates depend on taxable income, tax assumptions and future events.
- MyChem integration and earn-out or retention obligations, Alphazyme purchase economics, and the timing and returns from planned capital spending and BARDA-supported construction.